Skip to main content
SpringerLink
Log in

Detection of Her-2/Neu Cep 17 Mutations at Invasive Bladder Cancer

  • Chapter
Bladder Disease, Part A

  • 302 Accesses

Abstract

Transitional cell carcinoma (TCC) of the urinary bladder is the eighth most common cancer in Germany;1 the tumor varies greatly in its biological behavior. Of superficial TCC (Ta, Tl), up to 70% will eventually be recurrent; 10 to 15% will progress to muscle invasion (≥ T2).4 About 50% of patients with muscle-invasive bladder tumors subsequently develop metastases.34,35

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Becker N, Wahrendorf J: Krebsatlas der Bundesrepublik Deutschland 1981–1990. Berlin: Springer-Verlag, 1997.

    Google Scholar 

  2. Berger CS, Sandberg AA, Todd IA, Pennington RD, Haddad FS, Hecht BK, et al: Chromosomes in kidney, ureter, and bladder cancer. Cancer Genet Cytogenet, 23:1, 1986.

    Article  PubMed  CAS  Google Scholar 

  3. Berger CS, Lutz MD, Miles BJ, Farah RN, Weiss L, Van Dyke DL: Tumor behaviour in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Cancer Res, 47:6800, 1987.

    Google Scholar 

  4. Bichler K-H, Einführung: In: K-H. Bichler et al, eds. Diagnostik und Therapie des Harnblasenkarzinoms, Reinbek: Einhorn-Presse Verlag, 9–13, 1998.

    Google Scholar 

  5. Bichler K-H, Wechsel HW, Lahme S, Wilbert DM, Strohmaier WL: Die Stellung der transurethralen Elektroresektion in der Behandlung des Harnblasenkarzinoms (differenzierende transurethrale Resektion). In: K-H. Bichler et al., eds. Diagnostik und Therapie des Harnblasenkarzinoms, Reinbek: Einhorn-Presse Verlag, 82–91. 1998.

    Google Scholar 

  6. Böcking A, Schunk K, Auffermann W: Exfoliative-cytologic diagnosis of basal-cell carcinoma with the use of DNA image cytometry. Acta Cytologica, 31:143, 1987.

    PubMed  Google Scholar 

  7. Böcking A: Diagnostische DNS-Zytometrie des Urothels. In: Rathert P, Roth S, eds. Urinezytologie. Berlin: Springer Verlag, 147–170, 1995.

    Google Scholar 

  8. Böhm N: Einfluß der Fixierung und der Säurekonzentration auf die Feulgen-Hydrolyse bei 28°C. Histochemie, 14:201, 1968.

    Article  PubMed  Google Scholar 

  9. Böhm N, Sprenger E, Schluter G, Sandritter W: Proportionalitätsfehler bei der Feulgen-Hydrolyse. Histochemie, 15:194, 1968.

    Article  PubMed  Google Scholar 

  10. Coomb LM, Pigott DA, Sweeney E: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer, 63:601, 1991.

    Article  Google Scholar 

  11. Cremer TH, Jauch A, Ried TH, Schöck E, Lengauer CH, Cremer M, et al: Fluoreszenz-in-situ-Hybridisierung. Dt Ärzteblatt, 22:1177, 1985.

    Google Scholar 

  12. Feulgen R, Rosenbeck H: Mikroskopisch-chemischer Nachweis einer Nucleinsäure vom Typus der Thymonucleinsäure und die darauf beruhende elektive Färbung von Zellkulturen in mikroskopischen Präparaten. Zeitschrift für Physiologische Chemie, 135:203, 1924.

    Article  CAS  Google Scholar 

  13. Fisher HAG, White MD, Graber MW, Sheehan CE, Ross JS: Use of HER-2/neu gene expression to predict clinical outcome in patients with transitional cell carcinoma of the urinary bladder. J Urol, 159:165, 1998.

    Google Scholar 

  14. Gibas Z, Prout GR, Connolly Jr. JG, Pontes JE, Sandberg AA: Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res, 44:1257, 1984.

    PubMed  CAS  Google Scholar 

  15. Graumann W: Zur Standardisierung des Schiffschen Reagens. Zt wissenschaftliche. Mikroskopie, 61:225, 1953.

    Google Scholar 

  16. Hermanek P, Sobin LK: UICC International Union Against Cancer. In: TMN Classification of Malignant Tumours. Berlin: Springer Verlag, 133–135, 1987.

    Chapter  Google Scholar 

  17. Hopmann AH, Poddighe PJ, Smeets AW, Moesker O, Beck JL, Vooijs GP, et al: Detection of numerical chromosome aberrations in bladder cancer by in situ hybridization. Am J Pathol, 135:1105, 1989.

    Google Scholar 

  18. Hopmann AH, Moesker O, Smeets AWGB, Pauwels RPE, Vooijs GP, Rameakers FC: Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res, 51:644, 1991.

    Google Scholar 

  19. Hurwitz E, Stancovski I, Sela M, Yarden Y: Suppression and promotion of tumor growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake. Proc Natl Acad Aci USA, 92:3353, 1985.

    Article  Google Scholar 

  20. Jacobellis U, Paradisco A, Tommasi S, Ricco R, Napoli A, Catucci O, et al: HER-2/neu in bladder carcinoma. Acta Urol Ital, 13(2): 129, 1999.

    Google Scholar 

  21. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufmann Jr RP, Muraca PJ, et al: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplifikation with recurrence in prostatic adenocarcinomas. J Clin Oncol, 16:1302, 1998.

    PubMed  CAS  Google Scholar 

  22. Lau JLT, Fowler JE, Ghosh L: Epidermal growth factor in the normal and neoplastic kidney and bladder. J Urol, 139:175, 1988.

    Google Scholar 

  23. Mahdy E, Yoshihiro S, Zech L, Wester K, Pan Y, Busch C, et al: Comparison of comparative genomic hybridisation, fluorescence in situ hybridisation and flow cytometry in urinary bladder cancer. Anticancer Res, 19:7, 1999.

    PubMed  CAS  Google Scholar 

  24. Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HS, Smith D, et al: Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res, 52:3474, 1992.

    PubMed  CAS  Google Scholar 

  25. Mayall BH: Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res, 51:3807, 1991.

    PubMed  Google Scholar 

  26. Meloni MM, Peier AM, Hadard FS, Powell IJ, Block AMW, Huben RP, et al: A new approach in the diagnosis and follow up of bladder cancer. Cancer Genet Cytogenet, 71:105, 1993.

    Article  PubMed  CAS  Google Scholar 

  27. Neal DE, Sharpies L, Smith K, Fenelly J, Hall RR, Harris AL: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65:1619, 1990.

    Article  PubMed  CAS  Google Scholar 

  28. Nemoto R, Nakamur I, Uchida K, Harada M: Numerical chromosome aberrations in bladder cancer detected by in situ hybridization. Br J Urol, 75:470, 1995.

    Article  PubMed  CAS  Google Scholar 

  29. Presti JC, Reuter VE, Galan T, Fair WR, Cordon-Cardo C: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res, 51:5405, 1991.

    PubMed  Google Scholar 

  30. Pycha A, Mian C, Hofbauer J, Brossner C, Haitel A, Wiener H, et al: Multifocality of transitional cell carcinoma results from genetic instability of entire transitional epithelium. Urology 53:92, 1999.

    Article  PubMed  CAS  Google Scholar 

  31. Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS: Identification of Her-2/neu oncogene amplification by fluorescence in situ hybridisation in stage I endometrial carcinoma. Mod Pathol, 10:823, 1997.

    PubMed  CAS  Google Scholar 

  32. Rubben H, Lutzeyer W, Wallace DMA: The epidemiology and etiology of bladder cancer. In: Bladder Cancer. Berlin: Springer-Verlag, 1985.

    Google Scholar 

  33. Sandberg AA, Berger CS: Review of chromosome studies in urological tumors: Cytogenetics and molecular genetics of bladder cancer. J Urol, 151:545, 1994.

    PubMed  CAS  Google Scholar 

  34. Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldmann FM: Chromosome-9 loss detected by fluorescence on situ hybridisation in bladder cancer. Int J Cancer, 64:99, 1995.

    Article  PubMed  CAS  Google Scholar 

  35. Schalken JA, Schalken MJ: Prognostic indicators of bladder cancer. Cur Opinon Urol, 5:272, 1995.

    Google Scholar 

  36. Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Proc Natl Acad SCI USA, 82:6497, 1985.

    Article  PubMed  CAS  Google Scholar 

  37. Slamon DJ, Godolphin W, Jones LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244:707, 1989.

    Article  PubMed  CAS  Google Scholar 

  38. Vanni R, Peretti D, Scarpa RM, Usai E: Derivative 11 marker chromosome in bladder carcinoma. Cancer Genet Cytogenet, 164:289, 1985.

    Article  Google Scholar 

  39. Werner W, Junker K, Ebert W, Muller C, Schubert J: Zytogenetische Veränderungen beim Harnblasenkarzinom — Einsatz der Fluoreszenz-In-Situ-Hybridisierung (FISH). In: Bichler K-H et al., eds. Diagnostik und Therapie des Harnblasenkarzinoms. Reinbek: Einhorn-Presse Verlag, 350, 1998.

    Google Scholar 

  40. Wheeless LL, Reeder JE, Han MJ, O’Connell R, Frank IN, Cockett ATK, et al: Bladder irrigation specimens assayed by fluoresence in situ hybridisation to interphase nuclei. Cytometry-, 17:319, 1994.

    Article  PubMed  CAS  Google Scholar 

  41. Yokata J, Yamamoto T, Toyoshima K: Amplification of c-erbB-2 oncogene in human adenocarcinomatas in vivo. Lancet, 1:765, 1986.

    Article  Google Scholar 

  42. Zhang FF, Arber DA, Wilson TG, Kawachi MH, ad Slovak ML: Toward the validation of aneusomy detection by fluorescence in situ hybridisation in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical feature predicts recurrence and defines clinical testings limitations. Clin Cancer Res, 3:2317, 1997.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Eberhard-Karls-University of Tuebingen, Tübingen, Germany

    Gerhard Feil, F. Steffen Krause, Andreas Zumbraegel & Karl-H. Bichler

Authors
  1. Gerhard Feil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Steffen Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Zumbraegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karl-H. Bichler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Children’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

    Anthony Atala

  2. Ridgefield, Connecticut, USA

    Debra Slade

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Feil, G., Krause, F.S., Zumbraegel, A., Bichler, KH. (2003). Detection of Her-2/Neu Cep 17 Mutations at Invasive Bladder Cancer. In: Atala, A., Slade, D. (eds) Bladder Disease, Part A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8889-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-8889-8_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4707-1

  • Online ISBN: 978-1-4419-8889-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation